Stockscreener 앱 받기
0.4406
3.44%
-0.0157
전일 마감가:
$0.4563
열려 있는:
$0.479
하루 거래량:
810.59K
Relative Volume:
1.20
시가총액:
$19.79M
수익:
-
순이익/손실:
$-123.46M
주가수익비율:
-0.1701
EPS:
-2.59
순현금흐름:
$-104.11M
1주 성능:
+36.07%
1개월 성능:
+20.05%
6개월 성능:
-77.86%
1년 성능:
-80.42%
1일 변동 폭
$0.422
$0.4799
1주일 범위
$0.30
$0.4799
52주 변동 폭
$0.2601
$3.5299
바이오아틀라 Stock (BCAB) Company Profile
명칭
Bioatla Inc
전화
858-558-0708
주소
11085 TORREYANA ROAD, SAN DIEGO
BCAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.4406 | 19.79M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오아틀라 Stock (BCAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 개시 | JMP Securities | Mkt Outperform |
| 2022-05-05 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-06-28 | 개시 | ROTH Capital | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | BTIG Research | Buy |
| 2021-01-11 | 개시 | Credit Suisse | Outperform |
| 2021-01-11 | 개시 | JP Morgan | Overweight |
| 2021-01-11 | 개시 | Jefferies | Buy |
모두보기
바이오아틀라 주식(BCAB)의 최신 뉴스
BioAtla Inc (BCAB) Could Be Worth Considering For The Next Few Weeks - Stocksregister
BioAtla announces poster presentations at 2025 AACR meeting - TipRanks
How did BioAtla Inc (BCAB) fare last session? - uspostnews.com
BCAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
BioAtla (BCAB) to Showcase Innovative Cancer Research at 2025 Co - GuruFocus
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Cancer Treatment Breakthrough: BioAtla's Novel Drug Outperforms Standard Therapy in Multiple Cancers - Stock Titan
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
BioAtla, Inc. to Present Phase 2 Trial Results of Ozuriftamab Vedotin at ASCO 2025 Annual Meeting - Nasdaq
New Phase 2 Cancer Drug Data: BioAtla's Head and Neck Cancer Treatment Results at ASCO 2025 - Stock Titan
BioAtla stock holds $1 target, Market Outperform rating By Investing.com - Investing.com Nigeria
BioAtla stock holds $1 target, Market Outperform rating - Investing.com Australia
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Norges Bank Makes New Investment in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla's SWOT analysis: oncology biotech's stock faces pivotal year - Investing.com
BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year By Investing.com - Investing.com South Africa
BioAtla’s SWOT analysis: oncology biotech’s stock faces pivotal year - Investing.com India
HC Wainwright Has Optimistic Outlook of BioAtla Q1 Earnings - Defense World
FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright - Defense World
BioAtla (NASDAQ:BCAB) Given “Neutral” Rating at HC Wainwright - Defense World
BioAtla stock price target cut to $1 by Citizens JMP - Investing.com Australia
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
BioAtla price target lowered to $1 from $5 at Citizens JMP - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call Transcript - MSN
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky - Yahoo Finance
BioAtla’s Earnings Call: Clinical Progress and Strategic Outlook - TipRanks
BioAtla stock price target cut to $10 at BTIG, retains Buy rating - Investing.com Canada
BioAtla stock price target cut to $10 at BTIG, retains Buy rating By Investing.com - Investing.com South Africa
BioAtla Inc. (BCAB) reports earnings - Quartz
BioAtla, Inc. SEC 10-K Report - TradingView
BioAtla Inc: Weathering Stock Market Storms with 22.78M Market Cap - investchronicle.com
BioAtla, Inc. Reports 2024 Financial Results and Clinical Progress - TipRanks
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock rises - Investing.com India
BioAtla announces restructuring, to cut over 30% of workforce - TipRanks
BioAtla reports Q4 Net loss ($14.9M) vs ($26.9M) last year - TipRanks
Bioatla IncAnnounces 30% Workforce Reduction - MarketScreener
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress - The Manila Times
Earnings Outlook For BioAtla - Benzinga
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings - Quantisnow
BioAtla, Inc. Announces Abstract Presentations at European Lung Cancer Congress and Mayo Clinic Symposium 2025 - Nasdaq
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025 - Quantisnow
바이오아틀라 (BCAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):